Antitumor and Antiviral Activity of Pentacyclic Triterpenes
Over the last two decades, extensive research on compounds isolated from fruits, vegetables, cereals, herbs and medicinal plants has revealed that triterpenoids possess important pharmacological properties. Among the group of triterpenoids, pentacyclic ones show wide range of extensively
studied pharmacokinetics linked with anticancer and antiviral action. In the group of pentacyclic triterpenoids the most active against cancer development are asiatic acid (AA), betulinic acid (BetA), boswellic acid (BA), glycyrrhizin and 18β-glycyrrhetinic acid (GA), lupeol, oleanolic
acid (OA) or ursolic acid (UA) and their analogs and derivatives. They exhibit a cytotoxic action against a variety of tumor cell lines comparable to some clinically used drugs. Most of them have also important antiviral properties, especially anti-HIV activity, which make them potentially
useful additives to the current anti-HIV therapy. The literature concerning studies on both, anticancer and antiviral activities of pentacyclic triterpenes is reviewed.
Keywords: Antitumor; antiviral; triterpenes
Document Type: Research Article
Publication date: 01 August 2014
- Mini-Reviews in Organic Chemistry publishes original reviews on all areas of organic chemistry including synthesis, bioorganic, medicinal, natural products, organometallic, supramolecular, molecular recognition, and physical organic chemistry. The emphasis will be on publishing quality papers very rapidly. Mini-reviews will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts.
The journal is essential reading to all organic chemists in both academia and industry. - Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content